BioMarin Pharmaceutical Inc.
HealthcareNASDAQ:BMRN · NASDAQ Global Select
+$0.41 today
Vol 1.07M · Avg 2.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
5.7%
avg 0.1%
ROIC
5.6%
avg 0.6%
ROA
4.6%
avg 0.4%
Analysis
ROE is currently the strongest return metric at 5.7% versus its period average of 0.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alexander Hardy | President, Chief Executive Officer & Director | $3.18M | — | 57 | $214,635.00 | 0.11% |
George Eric Davis | Executive VP, Chief Legal Officer & Secretary | $1.31M | — | 55 | $78,560.00 | 0.04% |
Brian R. Mueller | CFO & Executive VP of Finance | $1.31M | — | 52 | $123,314.00 | 0.06% |
Cristin Hubbard | Executive Vice President & Chief Commercial Officer | $1.29M | — | — | $42,472.00 | 0.02% |
Gregory Friberg | Executive Vice President and Chief Research & Development Officer | $1.28M | — | — | $51,818.00 | 0.03% |
C. Greg Guyer | Executive Vice President & Chief Technology Officer | $1.27M | — | 64 | $84,140.00 | 0.04% |
Ganesh Vedantham | Senior Vice President of Technical Development | — | — | — | — | — |
Arpit Dave | Executive Vice President, Chief Digital & Information Officer | — | — | — | — | — |
Amy Wireman | Executive Vice President & Chief People Officer | — | — | — | — | — |
Rashmi Eshwar Ramchandani | VP, Chief Accounting Officer & Principal Accounting Officer | — | — | 47 | $25,610.00 | 0.01% |
Kevin Eggan | Chief Scientific Officer & Senior Vice President of Research and Early Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
4
$3.15M
Net Sentiment
$3.15M
Net selling
Most Active
Friberg Gregory R
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 4 sells worth $3.15M over the last 12 months. That adds up to net selling of $3.15M. Friberg Gregory R was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A12 analysts |
| Revenue | N/A | N/A | +21.1% | +12.8% (15yr)9 analysts |
| Net Income | N/A | N/A | N/A | N/A9 analysts |
| EBIT | N/A | N/A | N/A | N/A9 analysts |
Analysis
Recent growth has been strongest in Revenue at +21.1% over three years. Forward estimates point to Revenue at +12.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.71B
Moderna, Inc.
NASDAQ:MRNA
$19.80B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.08B
Align Technology, Inc.
NASDAQ:ALGN
$12.52B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.08B
Bio-Techne Corporation
NASDAQ:TECH
$8.45B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Qiagen N.V.
NYSE:QGEN
$7.64B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages BMRN?
BioMarin Pharmaceutical Inc. (BMRN) lists 11 active executives. The top listed executive is Alexander Hardy, President, Chief Executive Officer & Director.
Are BMRN insiders buying or selling?
Recent insider activity shows net buying of $1.72M.
Explore More
Continue the stock analysis
Jump to another research area for this company.